1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > MediPost Co., Ltd. - Product Pipeline Review - 2015

MediPost Co., Ltd. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 26 pages

MediPost Co., Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘MediPost Co., Ltd. - Product Pipeline Review - 2015’, provides an overview of the MediPost Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MediPost Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of MediPost Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of MediPost Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the MediPost Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate MediPost Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of MediPost Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the MediPost Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of MediPost Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of MediPost Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of MediPost Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

MediPost Co., Ltd. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
MediPost Co., Ltd. Snapshot 4
MediPost Co., Ltd. Overview 4
Key Information 4
Key Facts 4
MediPost Co., Ltd. - Research and Development Overview 5
Key Therapeutic Areas 5
MediPost Co., Ltd. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
MediPost Co., Ltd. - Pipeline Products Glance 9
MediPost Co., Ltd. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Phase 0 Products/Combination Treatment Modalities 11
MediPost Co., Ltd. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
MediPost Co., Ltd. - Drug Profiles 13
Pneumostem 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
human umbilical cord blood-derived mesenchymal stem cells 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Neurostem 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
MediPost Co., Ltd. - Pipeline Analysis 20
MediPost Co., Ltd. - Pipeline Products by Route of Administration 20
MediPost Co., Ltd. - Pipeline Products by Molecule Type 21
MediPost Co., Ltd. - Recent Pipeline Updates 22
MediPost Co., Ltd. - Dormant Projects 23
MediPost Co., Ltd. - Locations And Subsidiaries 24
Head Office 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 25
Disclaimer 26

List of Tables
MediPost Co., Ltd., Key Information 4
MediPost Co., Ltd., Key Facts 4
MediPost Co., Ltd. - Pipeline by Indication, 2015 6
MediPost Co., Ltd. - Pipeline by Stage of Development, 2015 7
MediPost Co., Ltd. - Monotherapy Products in Pipeline, 2015 8
MediPost Co., Ltd. - Phase II, 2015 9
MediPost Co., Ltd. - Phase I, 2015 10
MediPost Co., Ltd. - Phase 0, 2015 11
MediPost Co., Ltd. - Preclinical, 2015 12
MediPost Co., Ltd. - Pipeline by Route of Administration, 2015 20
MediPost Co., Ltd. - Pipeline by Molecule Type, 2015 21
MediPost Co., Ltd. - Recent Pipeline Updates, 2015 22
MediPost Co., Ltd. - Dormant Developmental Projects,2015 23

List of Figures
MediPost Co., Ltd. - Pipeline by Top 10 Indication, 2015 6
MediPost Co., Ltd. - Pipeline by Stage of Development, 2015 7
MediPost Co., Ltd. - Monotherapy Products in Pipeline, 2015 8
MediPost Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015 20
MediPost Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) ...

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2016

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glial Cell Line Derived Neurotrophic Factor (Astrocyte ...

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016

  • $ 2500
  • Company report
  • October 2016
  • by Global Markets Direct

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016, ...

Ageing - Pipeline Review, H2 2016

October 2016 $ 2000

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.